IRIS Accounts Production v24.3.2.46 09001625 Board of Directors 1.10.23 30.9.24 30.9.24 0 false true false false true false Ordinary 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh090016252023-09-30090016252024-09-30090016252023-10-012024-09-30090016252022-09-30090016252022-10-012023-09-30090016252023-09-3009001625ns15:EnglandWales2023-10-012024-09-3009001625ns14:PoundSterling2023-10-012024-09-3009001625ns10:Director12023-10-012024-09-3009001625ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3009001625ns10:SmallEntities2023-10-012024-09-3009001625ns10:AuditExempt-NoAccountantsReport2023-10-012024-09-3009001625ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3009001625ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3009001625ns10:FullAccounts2023-10-012024-09-3009001625ns10:OrdinaryShareClass12023-10-012024-09-3009001625ns10:Director22023-10-012024-09-3009001625ns10:Director32023-10-012024-09-3009001625ns10:Director42023-10-012024-09-3009001625ns10:Director52023-10-012024-09-3009001625ns10:Director62023-10-012024-09-3009001625ns10:RegisteredOffice2023-10-012024-09-3009001625ns5:CurrentFinancialInstruments2024-09-3009001625ns5:CurrentFinancialInstruments2023-09-3009001625ns5:Non-currentFinancialInstruments2024-09-3009001625ns5:Non-currentFinancialInstruments2023-09-3009001625ns5:ShareCapital2024-09-3009001625ns5:ShareCapital2023-09-3009001625ns5:SharePremium2024-09-3009001625ns5:SharePremium2023-09-3009001625ns5:RetainedEarningsAccumulatedLosses2024-09-3009001625ns5:RetainedEarningsAccumulatedLosses2023-09-3009001625ns5:CostValuation2023-09-3009001625ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3009001625ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-3009001625ns10:OrdinaryShareClass12024-09-30
REGISTERED NUMBER: 09001625 (England and Wales)













Unaudited Financial Statements

for the Year Ended 30 September 2024

for

Heart Biotech Holdings Limited

Heart Biotech Holdings Limited (Registered number: 09001625)






Contents of the Financial Statements
for the Year Ended 30 September 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Heart Biotech Holdings Limited

Company Information
for the Year Ended 30 September 2024







DIRECTORS: M A Ishak-Hanna
S S Khouri
M C Radford
I A Richardson
M H Yacoub
F W White





REGISTERED OFFICE: 17 North Drive
Littleton
Winchester
SO22 6QA





REGISTERED NUMBER: 09001625 (England and Wales)





ACCOUNTANTS: Clive Owen LLP
Chartered Accountants
Kepier House
Belmont Business Park
Durham
DH1 1TW

Heart Biotech Holdings Limited (Registered number: 09001625)

Balance Sheet
30 September 2024

2024 2023
Notes £    £   
FIXED ASSETS
Investments 4 155,435 155,435

CURRENT ASSETS
Debtors 5 1 1,520,673

CREDITORS
Amounts falling due within one year 6 (291,637 ) (83,812 )
NET CURRENT (LIABILITIES)/ASSETS (291,636 ) 1,436,861
TOTAL ASSETS LESS CURRENT
LIABILITIES

(136,201

)

1,592,296

CREDITORS
Amounts falling due after more than one
year

7

(74,555

)

(81,920

)
NET (LIABILITIES)/ASSETS (210,756 ) 1,510,376

CAPITAL AND RESERVES
Called up share capital 8 71 71
Share premium 2,198,846 2,198,846
Retained earnings (2,409,673 ) (688,541 )
SHAREHOLDERS' FUNDS (210,756 ) 1,510,376

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Heart Biotech Holdings Limited (Registered number: 09001625)

Balance Sheet - continued
30 September 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 April 2025 and were signed on its behalf by:





F W White - Director


Heart Biotech Holdings Limited (Registered number: 09001625)

Notes to the Financial Statements
for the Year Ended 30 September 2024

1. STATUTORY INFORMATION

Heart Biotech Holdings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

There were no material departures from that standard.

The principal accounting policies adopted in the preparation of the financial statements are set out
below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.

Going concern
The directors assess whether the use of going concern is appropriate i.e. whether there are any materialities related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern. The directors make this assessment in respect of a period of at least one year from the date the financial statements are approved.

The financial statements are prepared on the going concern basis which assumes that the company will continue to trade. If the company is unable to continue to trade, adjustments would be required to reduce the value of assets to their recoverable amounts, to provide for any further liabilities that might arise and to analyse long term liabilities as current liabilities

Preparation of consolidated financial statements
The financial statements contain information about Heart Biotech Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost less impairment.

Financial instruments
Basic financial instruments are recognised at amortised cost with changed recognised in profit and loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - NIL ) .

Heart Biotech Holdings Limited (Registered number: 09001625)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 October 2023
and 30 September 2024 155,435
NET BOOK VALUE
At 30 September 2024 155,435
At 30 September 2023 155,435

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed by group undertakings - 1,520,672
Other debtors 1 1
1 1,520,673

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed to group undertakings - 2
Taxation and social security 11,290 -
Directors' current accounts 278,457 81,920
Accruals and deferred income 1,890 1,890
291,637 83,812

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Directors' loan accounts 74,555 81,920

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
7,125 Ordinary £0.01 71 71

Heart Biotech Holdings Limited (Registered number: 09001625)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

9. RELATED PARTY DISCLOSURES

There were no related party transactions other than those concluded under normal market conditions, except for those shown below.

2024 2023
£ £
Amounts due from group undertakings - 1,520,672

Amounts due to directors within one year 278,457 81,920

Amounts due to directors over one year 74,555 81,920

No interest has been charged.